The Value of New: Consideration of Product Novelty in Health Technology Assessments of Pharmaceuticals
Background Efforts to understand how treatments affect patients and society have broadened the criteria that health technology assessment (HTA) organizations apply to value assessments. We examined whether HTA agencies in eight countries consider treatment novelty in methods and deliberations. Methods We defined a novel pharmaceutical product to be one that offers a new approach to treatment (e.g., new mechanism of action), addresses an unmet need (e.g., targets a rare condition without effective treatments), or has a broader impact beyond what is typically measured in an HTA. We reviewed peer-reviewed publications and technical guidance materials from HTA organizations in Australia, Canada, England, France, The Netherlands, Norway, Sweden, and the United States (US). In addition, we explored how HTA organizations integrated novelty considerations into deliberations and recommendations related to two newer therapies—voretigene neparvovec for an inherited retinal disorder and ocrelizumab for multiple sclerosis. Results None of the HTA organizations acknowledge treatment novelty as an explicit value criterion in their assessments of pharmaceutical products. However, drugs that have novel characteristics are given special consideration, particularly when they address an unmet need. Several organizations document a willingness to expend more resources and accept greater evidence uncertainty for such treatments. Qualitative deliberations about the additional unquantified potential benefits of treatment may also influence HTA recommendations. Conclusion Major HTA organizations do not recognize novelty as an explicit value criterion, although drugs with novel characteristics may receive special consideration. There is an opportunity for organizations to codify their approach to evaluating novelty in value assessment..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
Applied health economics and health policy - 21(2022), 2 vom: 19. Dez., Seite 305-314 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Synnott, Patricia G. [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Anmerkungen: |
© The Author(s), under exclusive licence to Springer Nature Switzerland AG 2022. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
|---|
| doi: |
10.1007/s40258-022-00779-0 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR049345850 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR049345850 | ||
| 003 | DE-627 | ||
| 005 | 20230519184631.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230216s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s40258-022-00779-0 |2 doi | |
| 035 | |a (DE-627)SPR049345850 | ||
| 035 | |a (SPR)s40258-022-00779-0-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Synnott, Patricia G. |e verfasserin |0 (orcid)0000-0002-3824-4380 |4 aut | |
| 245 | 1 | 4 | |a The Value of New: Consideration of Product Novelty in Health Technology Assessments of Pharmaceuticals |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Springer Nature Switzerland AG 2022. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
| 520 | |a Background Efforts to understand how treatments affect patients and society have broadened the criteria that health technology assessment (HTA) organizations apply to value assessments. We examined whether HTA agencies in eight countries consider treatment novelty in methods and deliberations. Methods We defined a novel pharmaceutical product to be one that offers a new approach to treatment (e.g., new mechanism of action), addresses an unmet need (e.g., targets a rare condition without effective treatments), or has a broader impact beyond what is typically measured in an HTA. We reviewed peer-reviewed publications and technical guidance materials from HTA organizations in Australia, Canada, England, France, The Netherlands, Norway, Sweden, and the United States (US). In addition, we explored how HTA organizations integrated novelty considerations into deliberations and recommendations related to two newer therapies—voretigene neparvovec for an inherited retinal disorder and ocrelizumab for multiple sclerosis. Results None of the HTA organizations acknowledge treatment novelty as an explicit value criterion in their assessments of pharmaceutical products. However, drugs that have novel characteristics are given special consideration, particularly when they address an unmet need. Several organizations document a willingness to expend more resources and accept greater evidence uncertainty for such treatments. Qualitative deliberations about the additional unquantified potential benefits of treatment may also influence HTA recommendations. Conclusion Major HTA organizations do not recognize novelty as an explicit value criterion, although drugs with novel characteristics may receive special consideration. There is an opportunity for organizations to codify their approach to evaluating novelty in value assessment. | ||
| 700 | 1 | |a Voehler, Dominic |4 aut | |
| 700 | 1 | |a Enright, Daniel E. |4 aut | |
| 700 | 1 | |a Kowal, Stacey |4 aut | |
| 700 | 1 | |a Ollendorf, Daniel A. |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Applied health economics and health policy |d [S.l.] : Springer International, 2004 |g 21(2022), 2 vom: 19. Dez., Seite 305-314 |w (DE-627)SPR032968035 |w (DE-600)2180637-8 |x 1179-1896 |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2022 |g number:2 |g day:19 |g month:12 |g pages:305-314 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s40258-022-00779-0 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 21 |j 2022 |e 2 |b 19 |c 12 |h 305-314 | ||